Lumbar Intradiscal Platelet Rich Plasma Injections-A Multicenter, Prospective Study in Patients with Internal Disc Disruption

IRB Number: 2015-716

Institutional Review Board, Hospital for Special Surgery

August 01, 2016

The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.

Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.

For further information, see Understanding Clinical Trials.

Principal Investigator

Gregory Lutz, MD


Jennifer Solomon, MD
Richard Herzog, MD
Jonathan Kirschner, MD
Christopher Lutz, MD
Julian Harrison
Kwadwo Boachie-Adjei



This is a prospective, multicenter, study investigating the utility of intradiscal platelet rich plasma injections in patients with discogenic low back pain confirmed on discography. 10-12 study participants will be enrolled at Hospital for Special Surgery (70 total study participants at all sites) subsequently receive platelet rich plasma into the lumbar discs in which concordant pain is provoked via discography. The follow-up period (questionnaires on pain and function) will last for 1 year. Additionally, participants will undergo follow-up MRIs at 6 months after their injections.

Inclusion/Exclusion Criteria

Inclusion criteria:
 A high index of suspicion for discogenic pain, i.e. painful degenerative discs with or without protrusions < 3mm
 Age greater than 18 and less than 60 years
 Maintained intervertebral disc heights of at least 50%
 High intensity zone (HIZ) in annular fissure or adjacent to annular fissure detected on T2 or STIR MRI
 Pain that is unresponsive to conservative treatment measures (oral medication, epidural steroid injections, physical therapy)
 Pain persisting for an extended period of time (i.e., at least 3 months)
 Pain relieved transiently with an epidural injection of anesthetic and steroid or documentation of a painful Grade 3 or 4 annular fissure on discography (Modified Dallas Discogram Classification)
 No evidence of contraindications to undergo procedure such as pregnancy, active infection, bleeding disorder, or metastatic cancer
Exclusion criteria:
 Spinal Deformity (Scoliosis >20 degrees, Spondylolysis, Spondylolisthesis)
 Disc extrusions, sequestered fragments, severe thecal sac compression, or severe disc degeneration on MRI
 No transient relief of pain after a diagnostic epidural injection and/or lack of concordant pain/annular disruption on discography
 Presence of a Grade V annular fissure on discography
 Multi-level disease (> 2 levels of involvement)
 Prior lumbar surgery or intradiscal procedure (ie.IDET, Nucleoplasty)

Contact Information

Julian Harrison, BS
(212) 774-7386